Moxifloxacin and Sitafloxacin Treatment Failure in Mycoplasma genitalium Infection: Association with parC Mutation G248T (S83I) and Concurrent gyrA Mutations
Gerald L Murray, Kaveesha Bodiyabadu, Jennifer Danielewski, Suzanne M Garland, Dorothy A Machalek, Christopher K Fairley, Jorgen S Jensen, Deborah A Williamson, Lit Y Tan, Elisa Mokany, Duygu Durukan, Catriona S Bradshaw
The Journal of Infectious Diseases | OXFORD UNIV PRESS INC | Published : 2020
BACKGROUND: The basis of fluoroquinolone treatment failure for Mycoplasma genitalium is poorly understood. METHODS: To identify mutations associated with failure we sequenced key regions of the M. genitalium parC and gyrA genes for patients undergoing sequential therapy with doxycycline-moxifloxacin (201 patients, including 21 with failure) or doxycycline-sitafloxacin (126 patients, including 13 with failure). RESULTS: The parC G248T/S83I mutation was more common among patients with failed sequential doxycycline-moxifloxacin (present in 76.2% of failures vs 7.8% cures, P < .001) or doxycycline-sitafloxacin (50% vs 16.8%, respectively; P = .01) treatment. Doxycycline-sitafloxacin was more eff..View full abstract
Awarded by Department of Industry, Innovation and Science, Government of Australia
Awarded by National Health and Medical Research Council
This work was supported by the Department of Industry, Innovation and Science, Government of Australia (Innovations Connections grant ICG000220, jointly held with SpeeDx), the Department of Health, Government of Victoria (Victorian Medical Research Acceleration Fund, jointly held with SpeeDx) and the National Health and Medical Research Council (Early Career Fellowship grant GNT1123854 to D. A. W.).